Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Variagenics, Inc. (NasdaqNM:VGNX)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials | Reports
Recent Events
July 26Price hit new 52-week low ($3.03)
Location
60 Hampshire Street
Cambridge, MA 02139
Phone: (617) 588-5300
Fax: (617) 588-5399
Email: info@variagenics.com
Employees (last reported count): 89
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Products & Services
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 80%
·Institutional: 43% (212% of float)
(34 institutions)
·Net Inst. Buying: 3.53M shares (+26.14%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Variagenics, Inc. is engaged in the development and commercialization of technologies related to pharmacogenomics, which is the study of the correlation between an individual's genetic differences, or genetic variability, and his or her specific response to a drug. The most common form of this genetic variability is a single nucleotide polymorphism (SNP). The Company uses its pharmacogenomics technology, expertise and proprietary data to improve and enhance drugs in development and to identify and validate new drug targets. The Company also intends to use its technology to bring high-value diagnostic products to market. Variagenics is a pharmacogenomics company offering a full range of solutions to support key steps of the drug discovery and development process, extending from drug target identification through clinical trials to commercialization.
More from Market Guide: Expanded Business Description

Financial Summary
Variagenics, Inc. is engaged in the development and commercialization of technologies about pharmacogenomics, a study of the correlation between an individual's genetic differences, and his/her specific response to a drug. For the six months ended 6/30/01, revenues totaled $2 million, up from $276 thousand. Net loss applicable to Common fell 70% to $9.3 million. Results reflect increased collaboration revenue and product sales as well as the absence of preferred dividend payments.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

David Housman, Ph.D., 54
Chairman and Principal Scientific Advisor
--  
Taylor Crouch, 41
Pres, CEO, Director
$391K
Richard Shea, 49
CFO, VP of Fin. and Admin., Treasurer
209K
R. Mark Adams, Ph.D.
VP, Bioinformatics
--  
Ann Bailey, 56
VP, Diagnostic and Process Devel.
210K
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:VGNXAs of 31-Aug-2001
Price and Volume
52-Week Low
on 26-July-2001
$3.03 
Recent Price$3.42 
52-Week High
on 5-Sep-2000
$29.938
Daily Volume (3-month avg)109.4K
Daily Volume (10-day avg)34.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y]
52-Week Change-87.4%
52-Week Change
relative to S&P500
-83.1%
Share-Related Items
Market Capitalization$79.9M
Shares Outstanding23.4M
Float4.70M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$4.05 
Earnings (ttm)-$0.86 
Earnings (mrq)-$0.24 
Sales (ttm)$0.18 
Cash (mrq)$3.90 
Valuation Ratios
Price/Book (mrq)0.84 
Price/EarningsN/A 
Price/Sales (ttm)18.85 
Income Statements
Sales (ttm)$4.00M
EBITDA (ttm)-$15.4M
Income available to common (ttm)-$18.3M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-20.09%
Return on Equity (ttm)-24.78%
Financial Strength
Current Ratio (mrq)20.87 
Debt/Equity (mrq)0.04 
Total Cash (mrq)$91.1M
Short Interest
As of 8-Aug-2001
Shares Short24.0K
Percent of Float0.5%
Shares Short
(Prior Month)
24.0K
Short Ratio0.15 
Daily Volume159.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.